How can we foster a stronger partnership between patients, healthcare providers, researchers, and policymakers to improve outcomes for individuals living with these rare and autoimmune diseases?

Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ... Eculizumab is a long-acting humanized monoclonal antibody targeted against complement C5. It inhibits the cleavage of C5 into C5a and C5b and hence inhibits ... As anti-C5 therapy like eculizumab is the only treatment for patients with aHUS, optimizing treatment is indispensable. The drug label states that a trough ... Soliris Infusion Dosage and Administration. Patients receive eculizumab intravenously. Treatment time for a Soliris infusion at a medical clinic like IVX Health ... Eculizumab is a humanized monoclonal antibody directed against C5 of the complement cascade and thereby inhibits the formation of C5a and C5b-9 membrane attack ... Feb 22, 2023 ... This study demonstrates that the majority of patients benefit from eculizumab when adhering to the indications as formulated in the Dutch PNH guideline. ECULIZUMAB (ek yoo LYE zyoo mab) treats certain blood conditions that can cause low levels of red blood cells (anemia) and blood clots. Dec 12, 2022 ... It may be given to your child for other reasons. Talk with the doctor. Eculizumab. 2/11. Page 3 ... Soliris was approved by the U.S. Food and Drug Administration in 2019 for the treatment of adults with NMOSD who are positive for anti-AQP4 antibodies. The ... Jun 2, 2024 ... Both eculizumab and efgartigimod provide more treatment benefits to patients with generalized myasthenia gravis compared with conventional immunosuppressive ...